Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer

Gefitinib showed response in phase II clinical trials and with better clinical response in lung cancer with activating mutations in the tyrosine kinase domain of the EGFR. Questions of toxicity and potential dosing regimens impede the use in a prevention setting. This study will provide scientific e...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qi, Li, Ruichao, Chen, Xu, Lee, Sang Beom, Pan, Jing, Xiong, Donghai, Hu, Jiaqi, Miller, Mark Steven, Szabo, Eva, Lubet, Ronald A., Wang, Yian, You, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641144/
https://www.ncbi.nlm.nih.gov/pubmed/29069801
http://dx.doi.org/10.18632/oncotarget.19785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641144/
https://www.ncbi.nlm.nih.gov/pubmed/29069801
http://dx.doi.org/10.18632/oncotarget.19785

Ejemplares similares